TrialThe New England journal of medicine2011
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,249 papers cite itlatest 60 shown
this paperpooled ittrialcites it